Welcome to EpilepsyU.com a social network dedicated to the epilepsy community

Medicine

Zynerba’s cannabis-based epilepsy gel fails in phase 2 trial

Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial. The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo, ZYN002 during the treatment period could not show a statistically significant decrease in focal seizures in comparison to the baseline period for either the high or low dose cohorts. STAR expands to Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy. The patients in the phase 2 trial were randomized to be treated during a 12-week period for every 12 hours with either 195mg of ZYN002 4.2% CBD gel, 97.5mg of ZYN002 4.2% CBD gel or placebo gel. The primary...

Compound derived from marijuana interacts with anti-epileptic drugs

New research published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), suggests that an investigational neurological treatment derived from cannabis may alter the blood levels of commonly used anti-epileptic drugs. It is important for clinicians to consider such drug interactions during treatment of complex conditions.

Pairnomix, StemoniX Develop Epilepsy Model in Search for New Anti-seizure Drugs

Pairnomix has joined efforts with StemoniX to develop a lab-based model of epileptic seizures using so-called induced pluripotent stem cells (iPSCs). The model, which researchers refer to as a “seizure-in-a-dish” model system, will allow scientists to study seizures at a network level. In this way, they can use the model to screen for anti-epileptic drugs in a fast and easy manner. Minneapolis-based Pairnomix has expertise in epilepsy models, while San Diego-based StemoniX has developed the microBrain Platform. The model mirrors tissue architecture in the brain, with nerve cells connecting to each other through synapses, forming functional networks. For brain diseases such as epilepsy, iPSCs are invaluable research tools. These cells can be derived from skin tissue, and are forced to backt...

Data Lacking to Explain Why US Doctors Prefer Keppra to Treat Pediatric Epilepsy

Doctors have several anti-seizure options to treat epilepsy, but little data exists to show which of these treatments is best for children. Nevertheless, according to a recent study on therapies prescribed for children under 3 with epilepsy, doctors in the U.S. appear to prefer Keppra (levetiracetam) as either a first or second option for treatment.

Nearly Half of Persons With Epilepsy Forget to Take Their Meds at Least Once a Month, Poll Shows

Almost half of epilepsy patients surveyed in a British poll say they’ve forgotten to take their medications at least once in the past month. Researchers at Epilepsy Research UK wanted to know how meticulously people receiving their newsletter adhere to medication regimes. They stress, however, that these results pertain to a sample of 125 respondents and that the poll is still active. Medication adherence is an important healthcare problem worldwide. According to a news release, across all fields of medicine, up to 75 percent of people don’t take their medicines properly. In epilepsy, forgetting to take anti-epileptic drugs could lead to seizures. Respondents were asked to estimate for themselves how many times in the last month they had forgotten to take their medication at all – or had t...

Valproic Acid Concentration Drops With Ketogenic Diet

For patients with epilepsy, anti-epileptic drug serum concentrations remain stable during the ketogenic diet, apart from those of valproic acid, according to a study published online June 18 in the Journal of Clinical Pharmacy and Therapeutics. Changes in serum concentrations of other anti-epileptic drugs not found to be significant. For patients with epilepsy, anti-epileptic drug serum concentrations remain stable during the ketogenic diet (KD), apart from those of valproic acid, according to a study published online June 18 in the Journal of Clinical Pharmacy and Therapeutics.

Epilepsy and natural treatments: Can they help?

Epilepsy is a disease that disrupts the electrical activity of the nervous system, causing seizures. More than 65 million people in the world have epilepsy. 1 in 26 Americans will develop the disease during their lives. Children are the group most frequently diagnosed with new cases of epilepsy. In the United States, 300,000 children under 14 are affected by the condition. Some may outgrow the disorder, but most will not. The number of senior citizens with epilepsy is also 300,000. People with epilepsy have a range of treatment options, including alternative therapies. The illness is a complex condition, however, and all alternative treatment options must be looked at carefully, to ensure they are effective. Causes of epilepsy Epilepsy is a complex disease that can disrupt the electrical a...

In a first, marijuana substance reduces seizures for some epilepsy patients in clinical trial

For the first time, scientists have demonstrated that a component of cannabis reduces seizures in children with a rare form of epilepsy, marking a significant step in efforts to use marijuana and its derivatives to treat serious medical conditions.

High School Athlete With Epilepsy Fights to Bring CBD Oil on Campus

  A Georgia high school athlete has found himself in the middle of a medicinal cannabis debate, as school officials refuse to let the student, who suffers from epilepsy, take his medicinal cannabis oil on campus at lunch.

Epilepsy Seizure Treatment Trobalt to Be Discontinued in June 2017

GlaxoSmithkline (GSK) announced that its epilepsy seizure drug Trobalt (retigabine) will no longer be commercially available after June 2017. The company has advised healthcare providers to seek alternative medicines for patients as soon as possible and ensure that all patients are withdrawn from Trobalt by the end of June.

USFDA rejects SPARC’s epilepsy drug application

The US health regulator has denied approval to Sun Pharma Advanced Research Company’s (SPARC) new drug application for Elepsia XR, an anti-epileptic drug. The company has received a Complete Response Letter (CRL) from the USFDA for its new drug application for Elepsia XR, Levetiracetam extended-release tablets in strengths of 1,000 mg and 1,500 mg, SPARC said in a regulatory filing.

University of Warwick research focuses on absence epilepsy that affects children

A University of Warwick study to understand a form of epilepsy that affects children has received a grant from the charity Epilepsy Research UK. The research focuses on absence epilepsy which is largely a childhood condition which is characterized by sudden, brief interruptions of consciousness. In severe cases there may be more than 200 of these episodes each day, and these can be accompanied by or develop into convulsive seizures. Many children with absence seizures don’t respond to existing antiepileptic medication, which can present numerous difficulties in daily life, particularly with schooling.

Lost Password

Register